PolyPeptide Group AG (XSWX:PPGN) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 27, 2026)


XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
74 GF Score
Price CHF46.50
GF Value CHF30.72
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

PolyPeptide Group AG's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

XSWX:PPGN vs ZTS, UTHR, VTRS: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPeptide Group AG Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Margin of Safety % (DCF FCF Based) falls into.


XSWX:PPGN
74GF Score
PolyPeptide Group AG XSWX:PPGN
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF46.50 is trading 51.4% above its estimated GF Value™ of CHF30.72. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: CHF30.72 vs. price of CHF46.50 (51.4% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
74GF Score

Get the complete analysis for XSWX:PPGN

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF46.50
Price
CHF30.72
GF Value